Prevalence of non-conventional cardiovascular risk factors in Tunisian diabetics;Prévalence des facteurs de risque cardiovasculaire non conventionnels chez les sujets diabétiques tunisiens

Presse Medicale

Volumn 43, Issue 1, 2014, Pages

  Ben Ahmed, Habib ^a   Bouzid, Kahena ^a   Hassine, Meriam ^b   Saadi, Olfa ^c   Bahlous, Afef ^a   Abdelmoula, Jaouida ^a   Baccar, Hedi ^a   Ben Mami Ben Miled, Faika ^b  

^a CHARLES NICOLLE HOSPITAL   (Tunisia)

^b Institut National de Nutrition Tunis   (Tunisia)

^c SALAH AZAIEZ INSTITUTE   (Tunisia)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CYANOCOBALAMIN; FOLIC ACID; HOMOCYSTEINE; INSULIN;

ADULT; AMINO ACID BLOOD LEVEL; ARTICLE; BLOOD SAMPLING; CARDIOVASCULAR RISK; CONTROLLED STUDY; DIABETIC PATIENT; DISEASE ASSOCIATION; ECHOGRAPHY; ETHNIC GROUP; FATTY LIVER; FOLIC ACID BLOOD LEVEL; HUMAN; INSULINEMIA; MAJOR CLINICAL STUDY; METABOLIC SYNDROME X; MICROALBUMINURIA; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; PREVALENCE; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RISK FACTOR; SENSITIVITY ANALYSIS; TUNISIAN; VITAMIN BLOOD LEVEL;

ADULT; AGED; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; MALE; MIDDLE AGED; PREVALENCE; PROSPECTIVE STUDIES; RISK FACTORS; TUNISIA;

EID: 84892481861     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lpm.2013.07.019     Document Type: Article

References (34)

1. King H., Aubert R.E., Herman W.H. Global burden of diabetes, 1995-2025. Prevalence, numerical estimates, and projection. Diabetes Care 1998, 21:1414-1431.
2. Emoto M., Nischizawa Y., Maekawa K., Hiura Y., Kanda H., Kawagishi T., et al. Homeostasis model assessment as a clinical index of insulin resistance in type 2 diabetic patients treated with sulphonylureas. Diabetes Care 1999, 22:818-822.
3. Halimia J.M., Hadjadjb S., Aboyansc V. Microalbuminuria and urinary albumin excretion: French clinical practice guidelines. Diabetes Metab 2007, 33:303-309.
4. Mongkolsomlit S., Patumanond J., Tawichasril C., Komoltri C., Rawdaree P. Meta-regression of risk factors for microalbuminuria in type 2 diabetes. Southeast Asian J Trop Med Public Health 2012, 43:455-466.
5. Guerrero-Romero F., Rodríguez-Morán M. Relation of C-reactive protein to features of the metabolic syndrome in normal glucose tolerant, impaired glucose tolerant and newly diagnosed type 2 diabetic subjects. Diabetes Metab 2003, 29:65-71.
6. Lim S., Chellumuthi C., Crook N., Rush E., Simmons D. Low prevalence of retinopathy, but high prevalence of nephropathy among Maori with newly diagnosed diabetes - Te Wai o Rona: diabetes prevention study. Diab Res Clin Prac 2008, 80:271-274.
7. Yajnik C.S., Naik S.S., Raut K.N. Urinary albumin excretion rate (AER) in newly diagnosed type 2 Indian diabetic patients is associated with central obesity and hyperglycaemia. Diab Res Clin Pract 1992, 17:55-60.
8. Scheen A.J., Van Gaal L. pour les investigateurs de l'étude DANA (Diabetes Assistance and Nephropathy Aware-ness). Microalbuminurie, marqueur du syndrome pluri métabolique dans la population diabétique de type 2. Diabetes Metab 1998, 24:99.
9. Isomaa B., Almgren P., Tuomi T., Forsén B., Lahti K., Nissén M., et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001, 24:683-689.
10. Volpe M., Battistoni A., Tocci G., Rosei E.A., Catapano A.L., Coppo R., et al. Cardiovascular risk assessment beyond systemic coronary risk estimation: a role for organ damage markers. J Hypertens 2012, 30:1056-1064.
11. Nassib M., Khanouach H., Chadli A., Elghomari H., Farouqi A. Syndrome métabolique et diabète: profil cardiovasculaire. Diabetes Metab 2009, 35:42.
12. Iwasaki T., Togashi Y., Ohshige K., Yoneda M., Fujita K., Nakajima A., et al. Neither the presence of metabolic syndrome as defined by the IDF guideline nor an increased waist circumference increased the risk of microvascular or macrovascular complications in Japanese patients with type 2 diabetes. Diab Res and Clin Pract 2008, 79:427-432.
13. Chamontin B., Marr M. Insulinorésistance, hypertension artérielle et prévention cardiovasculaire. Press Med 1997, 14:671-677.
14. Bonora E., Kiechl S., Willeit J. Prevalence of insulin resistance in metabolic disorders. The Buneck Study. Diabetes 1998, 47:1643-1649.
15. Costa L.A., Canani L.H., Lisboa H.R., Tres G.S., Grooss J.L. Aggregation of the features of the metabolic syndrome is associated with increased prevalence of chronic complications in type 2 diabetes. Diabet Med 2004, 21:252-255.
16. Matsumoto K., Kizaki Y., Fukae S., Tomihira M., Sera Y., Ueki Y., et al. Insulin resistance and coronary risk factors in Japanese type 2 diabetic patients with definite coronary artery disease. Diab Res Clin Pract 2001, 51:181-186.
17. Esposito K., Nappo F., Marfella R., Giugliano G., Giugliano F., Ciotola M., et al. Inflammatory cytokine concentrations are acutely increased by hyperglycemia in humans. Circulation 2002, 106:2067.
18. Ford E.S. Body mass index, diabetes, and C-reactive protein among US adults. Diabetes Care 1999, 22:1971-1977.
19. Aouni Z., Oudi M., Ourtani H. Inflammation chronique subclinique et insulinorésistance chez les diabétiques non insulinodépendants. Immuno Analyse Biol Spec 2008, 23:353-357.
20. Calle M.C., Fernandez M.L. Inflammation and type 2 diabetes. Diabetes Metab 2012, 38:183-191.
21. Aruna D.P., JoAnn E.M., Nader R., Julie E.B., Paul M.R. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 2001, 286:327-334.
22. Noriyuki N., Tsunehito S., Mriko W. Association between fasting glucose and C-reactive protein in Japanese population: the Minoh study. Diabetes Res Clin Pract 2005, 69:88-98.
23. Faria-Neto J.R., Chagas A.C., Bydlowski S.P., Lemos Neto P.A., Chamone D.A., Ramirez J.A., et al. Hyperhomocystinemia in patients with coronary artery disease. Braz J Med Biol Res 2006, 39:455-463.
24. Buysshaert M., Dramais A.S., Wallemacq P., Hearmans M.P. Hyperhomocysteinemia in type 2 diabetes. Relationship to macroangiopathy, nephropathy, and insulinresistance. Diabetes Care 2000, 23:1816-1822.
25. Rudy A., Kowalska I., Straczkowski M., Kinalska I. Homocysteine concentrations and vascular complications in patients with type 2 diabetes. Diabetes Metab 2005, 31:112-117.
26. Hoogeveen E.K., Kostense P.J., Beks P.J., Mackaay A.J., Jakobs C., Bouter L.M., et al. Hyperhomocysteinemia is associated with an increased risk of cardiovascular disease, especially in non insulin-dependent diabetes mellitus. Arterioscler Thromb Vasc Biol 1998, 18:133-138.
27. Masaki T., Anan F., Anai M., Higuchi K., Tsubone T., Gotoh K., et al. Hyperhomocysteinemia is associated with visceral adiposity in Japanese patients in type 2 diabetes mellitus. Diab Res Clin Pract 2007, 77:168-173.
28. Ahmed M.H., Barakat S., Almobarak A.O. Non-alcoholic fatty liver disease and cardiovascular disease: has the time come for cardiologists to be hepatologistsα. J Obes 2012, 2012:483135.
29. Hongyun L., Longyi Z., Biao L., Xiaochun S., Danhong X. High prevalence of coronary heart disease in type 2 diabetic patients with non-alcoholic fatty liver disease. Arch Med Res 2009, 40:571-575.
30. Mohan V., Farooq S., Deepa M., Ravikumar R., Pitchumoni C.S. Prevalence of non-alcoholic fatty liver disease in urban south Indians in relation to different grades of glucose intolerance and metabolic syndrome. Diab Res Clin Pract 2009, 84:84-91.
31. Lautamaki R., Borra R., Iozzo P., Komu M., Lehtimäki T., Salmi M., et al. Liver steatosis coexists with myocardial insulin resistance and coronary dysfunction in patients with type 2 diabetes. Am J Physiol Endocrinol Metab 2006, 291:282-290.
32. Targher G., Bertolini L., Padovani R., Poli F., Scala L., Tessari R., et al. Increased prevalence of cardiovascular disease among type 2 diabetic patients with non-alcoholic fatty liver disease. Diabet Med 2006, 23:403-409.
33. Targher G., Byrne C.D. Non-alcoholic fatty liver disease: a novel cardiometabolic risk factor for type 2 diabetes and its complications. J Clin Endocrinol Metab 2013, 98:483-495.
34. Targher G., Bertolini L., Padovani R., Zenari L., Zoppini G., Falezza G. Relation of non-alcoholic hepatic steatosis to early carotid atherosclerosis in healthy men. Role of visceral fat accumulation. Diabetes Care 2004, 7:1498-1500.